



### 3.2. İSKELET SİSTEMİ BİFOSFONATLAR: YAPICI MI, YIKICI MI?



“Osteoporoz gibi yıkıcı bir hastalığa bifosfonatlar ile çözüm bulduk derken,  
bu ilaç vasıtasıyla yeni bir kemik hastalığına mı sebep olduk”

## KAYNAKLAR

- 1- Judith F. Sebestyen, Tarak Srivastava, Uri S. Alon Bisphosphonates Use in Children Clin Pediatr 2012 51: 1011
- 2- Neviasser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50.
- 3- Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
- 4- Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31.
- 5- Lenart BA, Neviasser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-62.
- 6- Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of micro-damage. Calcif Tissue Int 2001;69:281-6.
- 7- Jean-Pierre Devogelaer. Treatment of bone diseases with bisphosphonates, excluding osteoporosis Current Opinion in Rheumatology 2000,12:331-335
- 8- McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126(1):13-20.
- 9- Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9(8):1137-41.
- 10- Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119(4 Suppl 1): S25-31.
- 11- Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189-99.
- 12- Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82.
- 13- Reginster J, MinneHW, SorensenOH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11(1):83-91.
- 14- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24):2927-38.
- 15- Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19(8):1259-69.
- 16- Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011; 96(4):1006-1
- 17- Dell R, Greene D. Is osteoporosis disease management cost effective? Curr Osteoporos Rep 2010; 8(1):49-55.
- 18- Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and beddisability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000;160(1):77-85
- 19- Newman ED, Ayoub WT, Starkey RH, et al. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 2003;14(2):146-51.
- 20- Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011;22(9): 2551-6.
- 21- Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonate are associated with reduced mortality after hip fracture. Osteoporos Int 2011;22(3): 983-91.
- 22- Bolland MJ, Grey AB, Gamble GD, et al. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95(3):1174-81
- 23- Matthew T. Drake, Bart L. Clarke, Sundeep Khosla, Bisphosphonates: Mechanism of Action and Role in Clinical Practice Mayo Clin Proc. 2008 ; 83(9): 1032-1045
- 24- Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [letter]. N Engl J Med 2006;355(19):2048-2050.
- 25- Lenart BA, Lorch DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6.
- 26- Neviasser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorch DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-50.

## KAYNAKLAR

- 27- Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. *J Clin Endocrinol Metab* 2008;93:2948-52.
- 28- Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. *J Bone Joint Surg Br* 2007;89:349-53.
- 29- Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. *N Engl J Med* 2006;355:2048-50.
- 30- Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. *Hong Kong Med J* 2007;13: 485-9.
- 31- Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. *Calcif Tissue Int* 2009;85:37- 44.
- 32- Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. *J Bone Miner Res* 2009;24:1736-40.
- 33- Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker Rao D. Unusual mid-shaft fractures during long term bisphosphonate therapy. *Clin Endocrinol (Oxf)* 2009 March 19 (Epub ahead of print).
- 34- Capeci CM, Tejwani NC. Bilateral lowenergy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. *J Bone Joint Surg Am* 2009;91:2556-61.
- 35- Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. *Drug Saf* 2009;32:775-85.
- 36- Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. *J Bone Miner Res* 2009;24:1095-102.
- 37- Gun-II Im, Seung-Hyo Jeong Pathogenesis, Management and Prevention of Atypical Femoral Fractures *J Bone Metab* 2015;22:1-8
- 38- Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010;25:2267-949 3.
- 39- Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. *Bone* 2007;40:1144-51.
- 40- Tang SY, Allen MR, Phipps R, et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. *Osteoporos Int* 2009;20:887-94.
- 41- Vashishth D, Gibson GJ, Khoury JJ, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. *Bone* 2001;28:195-201.
- 42- Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. *J Bone Miner Res* 2006;21:1581-90.
- 43- Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. *Osteoporos Int* 2009;20:793-800.
- 44- Allen MR, Burr DB. Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone. *Bone* 2005;36:311-6.
- 45- Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. *Cancer Res* 2002;62:6538-44.
- 46- Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. *JPharmacol Exp Ther* 2002;302:1055-61.
- 47- Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. *Bone* 2006;39:872-9
- 48- Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. *Calcif Tissue Int* 2008;82:354-60.
- 49- Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. *Bone* 2001;28:524-31.
- 50- Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. *Bone* 2007;41:378-85.
- 51- Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. *J Bone Miner Res* 2007;22:1502-9.
- 52- Y.H. Ng, P.D. Gino, K. Lingaraj, S. Das De Femoral shaft fractures in the elderly – Role of prior bisphosphonate therapy. *Injury, Int. J. Care Injured* 42 (2011) 702–706

## KAYNAKLAR

- 53- Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. *J Bone Miner Res* 2011;26:553-60.
- 54- Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. *Osteoporos Int* 2010;21:399-408.
- 55- Feldstein A, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. *J Bone Miner Res* 2012;27:977-86.
- 56- Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med* 2011;364:1728-37
- 57- Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. *Bone* 2011;48:966-71
- 58- Wakenda Tyler, Susan Bukata, Regis O'Keefe Atypical Femur Fractures. *Clin Geriatr Med* 2014;30: 349-359
- 59- Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. *J Bone Miner Res* 2012;27(12):2544-50.
- 60- Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. *J Bone Miner Res* 2012;27(5):963-74.
- 61- Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and metaanalysis. *J Bone Miner Res* 2013;28(8):1729-37..
- 62- Anas Saleh, Vishal V. Hegde, BAAAnish G. Potty, Joseph M. Lane, Bisphosphonate Therapy and Atypical Fractures *Orthop Clin N Am* 44 (2013) 137-151
- 63- Salminen S, Pihlajamaki H, Avikainen V, et al. Specific features associated with femoral shaft fractures caused by low-energy trauma. *J Trauma* 1997; 43:117-22.
- 64- Salminen ST, Pihlajamaki HK, Avikainen VJ, et al. Population based epidemiologic and morphologic study of femoral shaft fractures. *Clin Orthop Relat Res* 2000;372:241-9.
- 65- Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. *Bone* 2011;48:966-71.
- 66- Feldstein A, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. *J Bone Miner Res* 2012;27:977-86.
- 67- Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. *Bone* 2001;28: 195-201.
- 68- Wang X, Shen X, Li X, et al. Age-related changes in the collagen network and toughness of bone. *Bone* 2002;31:1-7.
- 69- Tang SY, Zeenath U, Vashishth D. Effects of nonenzymatic glycation on cancellous bone fragility. *Bone* 2007;40:1144-51
- 70- Connolly JF, Guse R, Tiedeman J, et al. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. *Clin Orthop Relat Res* 1991; 266:259-70.
- 71- Hernigou P, Mathieu G, Poignard A, et al. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. *J Bone Joint Surg Am* 2006;88(Suppl 1 Pt 2):322-7.
- 72- Tiedeman JJ, Connolly JF, Strates BS, et al. Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix. An experimental study in dogs. *Clin Orthop Relat Res* 1991;268:294-302.
- 73- Tiedeman JJ, Garvin KL, Kile TA, et al. The role of a composite, demineralized bone matrix and bone marrow in the treatment of osseous defects. *Orthopedics* 1995;18:1153-8.
- 74- Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. *J Clin Endocrinol Metab* 2000;85:4118-24.